Cargando…

Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis

Objective This study represents the first 10 year analysis of the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of early low-risk prostate cancer. Materials and methods Two hundred and thirty males were treated with Cyberknife SBRT to a dose of 35 Gray (Gy) or 36.25...

Descripción completa

Detalles Bibliográficos
Autor principal:	Katz, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679773/ https://www.ncbi.nlm.nih.gov/pubmed/29152425 http://dx.doi.org/10.7759/cureus.1668

Ejemplares similares

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry
por: Davis, Joanne, et al.
Publicado: (2015)

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial
por: Zhao, Xianzhi, et al.
Publicado: (2022)

The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Koneru, Harsha, et al.
Publicado: (2016)

Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year Study
por: Katz, Alan Jay, et al.
Publicado: (2014)

Stereotactic body radiotherapy for organ-confined prostate cancer
por: Katz, Alan J, et al.
Publicado: (2010)

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes
por: Freeman, Debra E, et al.
Publicado: (2011)

Preoperative stereotactic body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumour thrombus: study protocol for a single-arm cohort trial
por: Liu, Yunchong, et al.
Publicado: (2022)

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years
por: Katz, Alan J, et al.
Publicado: (2013)

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
por: Kishan, Amar U., et al.
Publicado: (2019)

Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer
por: White, I D, et al.
Publicado: (2015)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?
por: Katz, Alan J., et al.
Publicado: (2011)

Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer
por: Katz, Alan, et al.
Publicado: (2012)

Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study
por: Katz, Alan, et al.
Publicado: (2014)

Editorial Comment: The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Correa, RJM, et al.
Publicado: (2020)

Using Google Trends and Twitter for Prostate Cancer Awareness: A Comparative Analysis of Prostate Cancer Awareness Month and Breast Cancer Awareness Month
por: Johnson, Bradley S, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure
por: Katz, Alan, et al.
Publicado: (2016)

The Effect of Radiotherapy on the Concentration of Plasma Lipids in Elderly Prostate Cancer Patients
por: Wolny-Rokicka, Edyta, et al.
Publicado: (2019)

Clostridium difficile Infection Is Associated With Decreased Prostate Cancer Risk: A Retrospective Cohort Study
por: Frankel, Lexi R, et al.
Publicado: (2023)

COmparing Urolift and Standard Transurethral resection of prostate Ahead of Radiotherapy in men with urinary symptoms secondary to prostate enlargement in Southwest London and North Cumbria (CO-STAR): a study protocol for a randomised feasibility study
por: Wong, Kathie, et al.
Publicado: (2023)

Evaluating variation in use of definitive therapy and risk-adjusted prostate cancer mortality in England and the USA
por: Sachdeva, Ashwin, et al.
Publicado: (2015)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Focal Cryoablation of the Prostate: Primary Treatment in 163 Patients With Localized Prostate Cancer
por: Khan, Anwar, et al.
Publicado: (2023)

Active surveillance for low-risk prostate cancer: well established, yet avoided?
por: Sosnowski, Roman, et al.
Publicado: (2022)

What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review
por: Kawa, Sandra Miriam, et al.
Publicado: (2020)

Clinical and Histopathological Characteristics of Prostate Cancer Patients Taken to Palliative Transurethral Prostate Resection
por: Rojas-Manrique, Juan P, et al.
Publicado: (2019)

Disseminated Intravascular Coagulation With Excessive Fibrinolysis Following Diagnostic Prostatic Biopsy for Prostate Cancer
por: Ghallab, Muhammad, et al.
Publicado: (2022)

High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial
por: Nair-Shalliker, Visalini, et al.
Publicado: (2021)

Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis
por: Zhao, Yi, et al.
Publicado: (2021)

Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI
por: Nordström, Tobias, et al.
Publicado: (2019)

Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results
por: Vuolukka, Kristiina, et al.
Publicado: (2020)

Psychological recovery and well-being of spouses of patients with prostate cancer 5 years after primary treatment in Finland: a follow-up survey
por: Lehto, Ulla-Sisko, et al.
Publicado: (2023)

Stereotactic ablative body radiotherapy in patients with prostate cancer
por: Loblaw, Andrew, et al.
Publicado: (2018)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Prostate Cancer Support Groups: The Unadvertised Camaraderie
por: Santarelli, Shana, et al.
Publicado: (2021)

The Predictive Value of Prostate-Specific Antigen Density: A Retrospective Analysis of Likert 3 Multiparametric MRI of the Prostate
por: Feyisetan, Oladapo, et al.
Publicado: (2023)

Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
por: Lott, Felipe
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lsuo2hgvhs5ehb4hrnoobgkjjq